Poussot climbs at Wyeth
This article was originally published in The Tan Sheet
Executive Summary
Bernard Poussot adds chief operating officer and board member to his titles at the Madison, N.J.-based firm, where he was named president and vice chairman in April 2006. Wyeth says Jan. 26 Poussot, 55, will add to his responsibilities leadership of the Wyeth Consumer Healthcare and Fort Dodge Animal Health and continue to lead the firm's Pharmaceuticals and R&D divisions. Poussot, who will continue to report to Chairman and CEO Robert Essner, began his career at Wyeth in 1986; in 1996 he was appointed president of Wyeth-Ayerst International and in 1997 became president of the worldwide pharmaceutical business before rising in 2002 to executive VP for R&D...
You may also be interested in...
Wyeth names new CEO
Wyeth announced Sept. 27 that Bernard Poussot will assume the position of CEO and president as of Jan. 1, 2008. Poussot will replace Robert Essner, who was elected CEO in May 2001 and became chairman in January 2003. Poussot began his career at Wyeth in 1986, and held positions including executive vice president until January 2007, when he was promoted to president, chief operating officer and vice chairman of Wyeth (1"The Tan Sheet" Jan. 29, 2007, In Brief). Essner will remain in his positions at Wyeth until Poussot's Jan. 1 start-date...
Roche/Genentech Keeps Commitment To External Cancer Innovation
Roche/Genentech oncology partnering maintained a robust dealmaking pace through the pandemic, keeping the percentage of partnered R&D programs at about 50% of the cancer drug pipeline.
US FDA Eases Changes For Certain Sterile Injectable Container Closure Materials
To mitigate pandemic disruption of component supply chains, the US FDA said it will downgrade some post-approval change categories for sterile drug container closure systems. The downgrade will cover drugs in shortage and those used to treat COVID-19.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: